Cancer Antigen 19-9 (CA 19-9)
| Product Name | Cancer Antigen 19-9 |
| Source | Human Liver Metastases |
| Catalogue Number | 151-99 |
| Purity | Highly Purified |
| Form | Liquid |
| Activity | Typically > 500 kU/mL (Roche Elecsys EIA) |
| Purity Note | High purity, low cross contamination of other cancer antigens |
| Purification | Gel filtration & ion-exchange chromatography |
| Formulation | Solution in phosphate buffered saline, pH 7.4 with sucrose and 0.05% sodium azide. |
| Appearance | Clear and Colorless |
| Pairing Information | Capture Ab: 151-91 - anti-Human CA 19-9 Monoclonal Antibody Detection Ab: 151-92 - anti-Human CA 19-9 Monoclonal Antibody Antigen: 151-99 - CA 19-9 from human metastatic liver |
| Storage | -20°C |
| Recertification | 3 years |
| Related Products | 151-25 - CA-125 antigen from human ascites fluid 151-53 - CA 15-3 antigen from human ascites fluid 151-10 - CEA antigen from human liver |
| Infectious Disease Testing | Negative or non-reactive at the donor level for anti-HIV 1 and 2, anti-HCV and HBsAg by FDA approved methods. |
| Synonyms | Tumor Marker 19-9, CA 19-9, Cancer Antigen 19-9, carbohydrate antigen 19-9, Sialylated Lewis (a) Antigen |
| Product Specificity | Gastrointestinal, Pancreatic Cancer |
Lee Biosolutions the leading producer and supplier of Cancer Antigen 19-9 (CA 19-9) for pancreatic management research and biomarker for manufacturing.
Custom preparations, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.
Cancer Antigen 19-9 is a tumor marker elevated in blood of patients with carcinoma of the gastro-intestinal tract. Primarily used distinguishing pancreatic cancer from pancreatitis, CA 19-9 is not sufficiently specific for use as a cancer screening test. The specificity for pancreatic cancer increases with increasing levels, high levels showing a specificity of >97% for tumor presence. CA 19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma.
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease.
Lee Biosolutions, Inc
